Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Cryptosporidium parvum oocysts (ABO809)
BIOLOGICAL
2 trials
Sponsors
Novartis Pharmaceuticals
Conditions
Cryptosporidiosis
Cryptosporidium Infection, Cryptosporidiosis
Phase 1
Study of Efficacy and Safety of ABO809 in Healthy Participants
Completed
NCT05036668
Novartis Pharmaceuticals
Cryptosporidium Infection, Cryptosporidiosis
Start: 2022-04-07
End: 2022-12-27
Updated: 2024-10-02
Phase 2
Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults
Recruiting
NCT07249463
Novartis Pharmaceuticals
Cryptosporidiosis
Start: 2025-12-08
End: 2027-03-23
Target: 80
Updated: 2026-08-19
Related Papers
Development of a Phase 1 Cryptosporidiosis Controlled Human Challenge Model in Healthy Volunteers Using Current Good Manufacturing Practice Cryptosporidium Parvum Oocysts and Conducted Under an Investigational New Drug Application.
2026-05-27